Acrivon Therapeutics Inc (ACRV)
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company focused on oncology. The company uses its generative phosphoproteomics platform and Acrivon Predictive Precision Proteomics, or AP3, to develop drug candidates alongside proprietary OncoSignature companion diagnostics designed to help identify patients most likely to respond. Its lead clinical program is ACR-368, a selective small-molecule CHK1 and CHK2 inhibitor being studied in endometrial cancer, platinum-resistant ovarian cancer, and certain squamous cell carcinomas, including head and neck and anal cancer. Acrivon is also advancing ACR-2316, a dual WEE1 and PKMYT1 inhibitor, as well as a preclinical cell cycle program built on AP3 and co-crystallography. The company was incorporated in 2018 and is based in Watertown, Massachusetts. The common stock trades on Nasdaq under the symbol ACRV.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACRV
|
$2.27
|
22.6% Upside
|
Undervalued
|
$11.50
|
521.6% Upside
|
Bargain
|
Fair
|
0.0%
|
November 12, 2026
|
0.9x
|
79.279 M
|
-8.565 M
|
2.8%
|
59.9%
|
0.3
|
86.4%
|
